* Spero Therapeutics Inc SPRO.OQ reported a quarterly
adjusted
loss of 33 cents per share for the quarter ended in June,
lower than the same quarter last year, when the company reported
EPS of -23 cents. The mean expectation of three analysts for
the quarter was for a loss of 38 cents per share. Wall Street
expected results to range from -45 cents to -25 cents per share.
* Revenue rose 275.4% to $10.20 million from a year ago;
analysts
expected $3.27 million.
* Spero Therapeutics Inc's reported EPS for the quarter was
a loss
of 33 cents.
* The company reported a quarterly loss of $17.86 million.
* Spero Therapeutics Inc shares had risen by 0.8% this
quarter and
lost 10.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 14.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Spero
Therapeutics Inc is $7.50
This summary was machine generated from LSEG data August 5 at
09:01 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.38 -0.33 Beat
Mar. 31 2024 -0.04 -0.24 Missed
Dec. 31 2023 -0.10 0.96 Beat
Sep. 30 2023 -0.03 0.04 Beat